From Sledgehammer to Selective: Transforming Cytotoxic Potency Through Targeted Treatments for Advanced or Metastatic Urothelial Cancer Evaluation (i776-3) Survey

Question Title

* 1. What is your degree?

MD/DO

Other (please specify)

Question Title

* 2. How many years have you been in practice?

≤ 1

1-10

11-20

≥ 21

Question Title

* 3. How many patients with urothelial cancer do you see weekly?

1 to 5

6 to 10

11 to 20

≥ 21

I am not directly involved in patient care

Question Title

* 4. Please select the option that best describes your practice setting:

Academic medical center

Community medical center

Other (please specify)

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with urothelial cancer?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make change

Question Title

* 8. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Constant changing guidelines

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Other (please explain)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC)	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Strongly agree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Agree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Neutral	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Disagree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Strongly disagree
Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Strongly agree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Agree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Neutral	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Disagree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Strongly disagree
Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments	Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments Strongly agree	Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments Agree	Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments Neutral	Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments Disagree	Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be paused by novel UC treatments Strongly disagree

Question Title

* 10. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Was fair, balanced and free from bias	Was fair, balanced and free from bias Strongly agree	Was fair, balanced and free from bias Agree	Was fair, balanced and free from bias Neutral	Was fair, balanced and free from bias Disagree	Was fair, balanced and free from bias Strongly disagree

Question Title

* 11. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 12. The faculty for this activity were knowledgeable?

Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 1. What is your degree?

Question Title

* 2. How many years have you been in practice?

Question Title

* 3. How many patients with urothelial cancer do you see weekly?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with urothelial cancer?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating. 5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagreeAfter participating in today’s activity, I am now able to:

Question Title

* 10. The content presented:

Question Title

* 11. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 12. The faculty for this activity were knowledgeable?

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 15. Address

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to: